New Jersey Chapter Meeting

Tuesday, June 12, 2012
6:00 PM – 9:00 PM

Basking Ridge Country Club
185 Madisonville Road
Basking Ridge, NJ  07920

Innovative Deal Making that Pivots on Collaboration among Competitors

Creative insights from three game-changing deals will highlight ways of bringing competition and cooperation together to achieve major gains for all.  Insights from these collaborations can be very valuable when negotiating complex biopharma deal structures, and will potentially encourage the development of other such deals.

The innovative deals featured are:

  • Pfizer’s landmark 5-member pharmaceutical consortium to fund Ablexis's development of the next generation AlivaMab, Mouse technology, for antibody drug discovery.
  • Enlight Biosciences partnerships with major pharmaceutical companies and leading academics to achieve breakthrough innovations.
  • The Merck/Roche clinical development collaboration deal to evaluate investigational combination regimens that include drugs from both companies for cHCV

Ruth Plager, President,  ZenithBIO Business Development Consultancy

Baruch Harris, Ph.D., Vice President, Strategy and Operations, Enlight Biosciences
Elaine V. Jones, PhD, Executive Director, Venture Capital - Worldwide Business Development,
Pfizer, Inc

Ellen Locker, Executive Director, Alliance Management, Merck & Co., Inc.
Peter M. Paciorek, PhD, Global Licensing Director, Roche Partnering, Hoffmann-La Roche Inc.

This is the chapter’s only meeting of the summer, so we hope you’ll be able to attend. We will resume in the fall, and in the meantime we wish you a great summer and enjoyable vacation breaks, where ever they may be!

6:00 PM - 7:30 PM
Cocktail Reception
7:30 PM - 9:00 PM
Program, Coffee & Dessert

Dress Code: Business or Business Casual

Early by: June 11
LES Member:            $40
LES Non-member:      $50
LES Student Member: $25

Regular & Onsite
LES Member:             $50
LES Non-member:      $60
LES Student Member: $25

Registration will include a networking cocktail reception with open bar, hors d'oeuvres, carving station, light buffet, coffee and dessert.

Online Registration Deadline: Monday, June 11, 12 PM EST

No refunds after June 11
Substitutions are permitted

Ruth Plager, President, ZenithBIO Business Development Consultancy.  In more than a decade of consulting, ZB’s strategic analyses and insights are being utilized to optimize corporate strategy, ongoing development plans, partnering and fund raising. A critical cornerstone of our consulting is our in-depth discussions and interviews with all key stakeholder groups—potential partners, investors, and end customers (physicians, patients, payers), as well as relevant deal perspective.

Ruth has created and produced more than a dozen innovative workshops, full-day interactive sessions, and plenary sessions  for  LES (Licensing Executive Society) at the Annual and Spring Meetings in  2007, 2008, 2009, 2010, 2011, 2012.

  • Issues and challenges discussed include deal discovery from licensor/ licensee and buyer/ seller perspectives, licensing issues in a world dominated by M&A, creative and flexible deal structures, assessment of partners and parallel negotiations.

Prior to ZenithBIO:  Ruth gained valuable “in-the-trench” experience at Pfizer in product management for hospital, specialty, and office-based products, at  Syntex International, Strategic Business Development & Marketing, and at Enzon Pharmaceuticals, Strategic Business Development & Marketing (biologics & drug delivery).

Education: B.S. from the University of Wisconsin; spent a year in cancer research at the Weizmann Institute of Science in Israel; and attended a series of Health Economics courses at Stanford’s Graduate School of Business.

Baruch Harris, PhD, Vice President, Strategy & Operations, Enlight Biosciences. Enlight Biosciences is a unique entrepreneurial partnership with major pharmaceutical companies and leading academics, focused on pioneering breakthrough innovations for drug discovery and development.  Baruch manages Enlight's day-to-day operations and provides management support to Enlight's portfolio companies.  He serves as Chief Business Officer for and is a member of the Board of Entrega, Inc., an Enlight portfolio company developing a groundbreaking technology for oral delivery of peptides, proteins, and poorly bioavailable small molecules. Prior to joining Enlight he was Executive Director and Head of Business Strategy and Operations for Novartis Biologics and an Engagement Manager at McKinsey & Company.  He received his Ph.D. in Biochemistry & Molecular Biology from the University of California, San Francisco, where he was a Howard Hughes pre-doctoral fellow, and his Sc.B. in Biophysics from Brown University with Honors, magna cum laude, where he was initiated into Sigma Xi.

Elaine V. Jones, Ph.D. joined Pfizer Venture Investments as Executive Director, Venture Capital in 2008.  Elaine is responsible for making and managing venture investments for Pfizer and currently manages the PVI investments in Aquinox Pharmaceuticals (Vancouver, British Columbia), Flexion Therapeutics (Boston, MA), Merus B.V. (Utrecht, The Netherlands), Neuronetics Inc. (Malvern, PA), NeuroTherapeutics Pharma (Chicago, IL), and TetraLogic Pharma (Malvern, PA).  Elaine brings 12 years of venture capital experience and a strong background in research and product assessment, built on her significant experience in pharmaceutical drug discovery and business development to the PVI team. 

Most recently, Elaine was a General Partner with the venture fund, EuclidSR Partners.  There, she was responsible for the fund’s investments in Acurian, Fluidigm, InnaPhase and Targacept. 

Prior to joining ESR, Dr. Jones began her private equity career in 1999 at S.R. One, GlaxoSmithKline’s venture fund, where she managed investments including  Adolor, Avantium, Nucleonics, Scynexis and Vicuron.  Previously, she served as Director of Scientific Licensing for SmithKline Beecham and was a research scientist in SmithKline Beecham Pharmaceutical R&D. 

Dr. Jones is a graduate of Juniata College and received her Ph.D. in Microbiology from the University of Pittsburgh.

Ellen Locker, Executive Director, Alliance Management at Merck & Co., Inc. is responsible for ensuring the smooth functioning of alliances between Merck and its partners, with programs at various stages of research, development and commercialization.

Ellen joined Merck in 1984 in the corporate finance area.  Desiring to play a more active role in shaping the business, she moved into Merck’s European Operations area as Director, Market Research and Strategic Planning in M.S.D. France.  Upon her return to the U.S., Ellen held positions of increasing responsibility in both Marketing and Human Resources.  As Director, Business and Organization Consulting, she was responsible for facilitating high level cross-functional teams tasked with developing business strategies at the therapy area level.  She then took on the position of Executive Director, Integrated Health and Employee Benefits, responsible for U.S. domestic employee benefits.  In her last position prior to moving into her current role, Ellen provided strategic decision support for the Cholesterol Partnership between Merck and Schering-Plough for Europe/Middle East & Africa.

Ellen has a B.A. in Biology from the University of Virginia and an M.B.A. from the College of William & Mary.

Peter Paciorek, PhD, Global Licensing Director, Roche Partnering, Hoffmann-La Roche Inc.  Peter has over 32 years of expertise in the pharmaceutical industry both in preclinical research and business development.   Peter has been in business development at Roche since 1996 and has been responsible for finding, evaluating and championing licensing opportunities across many disease areas.  Since 2001, Peter has been responsible for leading Roche transaction teams and has been involved in the successful negotiation of over 60 deals ranging from early research collaborations to complex co-promotion agreements. Prior to his career in business development, Peter worked for 16 years in various preclinical research positions at both Roche and Wyeth.

Peter has a BSc in Pharmacology/Physiology from the University of Leeds, and a PhD in Pharmacology from the CNAA, London, UK.

185 Madisonville Road
Basking Ridge, NJ 07920
(908) 766-8200

Take I-80 West to I-287 South to Exit 30A ( North Maple Ave. - Basking Ridge). Proceed to 1st traffic light. Make left onto Madisonville Road. Entrance is 2nd driveway on right.

Take I-287 North and proceed as above from Exit 30 A.

Take Garden State Parkway North. Exit onto I-287 North immediately after passing over the Raritan Bridge. Proceed as above from Exit 30 A.

Take I-78 East to Exit 29. Take I-287 North. Proceed as above from Exit 30 A.

Take I-78 West to Rte. 24 West toward Morristown. Take I-287 South and proceed as above from Exit 30 A.


Dolce (formerly North Maple Inn)
300 North Maple Avenue
Basking Ridge, NJ 07920
(908) 953-3000

The Inn at Somerset Hills
80 Allen Road
Basking Ridge, NJ 07920
(908) 580-1300

The Olde Mill Inn
225 Rt. 202
(at North Maple Avenue)
Basking Ridge, NJ 07920
(908) 221-1100

The Madison Hotel
One Convent Road
Morristown, NJ 07960
(973) 285-1800

The Hilton at Short Hills
41 JFK Parkway
Short Hills, NJ 07078
(973) 379-0100

 Somerset Hills Hotel
200 Liberty Corner Road
Warren, NJ 07059
(800) 688-0700

The Grand Summit Hotel
570 Springfield Avenue
Summit, NJ 07901
(908) 273-3000

Upcoming Events

Prior Events